F
Filip K. Knop
Researcher at University of Copenhagen
Publications - 523
Citations - 17834
Filip K. Knop is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Type 2 diabetes & Diabetes mellitus. The author has an hindex of 61, co-authored 437 publications receiving 13614 citations. Previous affiliations of Filip K. Knop include Copenhagen University Hospital & Victor Chang Cardiac Research Institute.
Papers
More filters
Journal ArticleDOI
Identification of genes involved in glucose-stimulated insulin secretion
Per Bo Jensen,Filip K. Knop,Gouxun Chen,Hans E. Hohmeier,Hindrik Mulder,Christopher B. Newgard +5 more
TL;DR: A genetic screen of strongly responsive and poorly responsive INS-1-derived clones to identify genes involved in glucose-stimulated insulin secretion (GSIS), which could lead to better understanding of type 2 diabetes and be a useful tool in generating insulin-secreting cell lines.
Journal ArticleDOI
Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study.
Jakob S. Knudsen,Reimar W. Thomsen,Anton Pottegård,Filip K. Knop,Filip K. Knop,Henrik Toft Sørensen +5 more
TL;DR: Comorbidities or diabetes complications were present in most patients, with the highest prevalence observed among the 73% of initiators who would have been ineligible for the Liraglutide Effect and Action in Diabetes (LEAD) 1-5 trials that led to liragLutide registration, underscoring the need for further post-marketing studies.
Journal ArticleDOI
No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course
Kristian Hallundbæk Mikkelsen,Tina Vilsbøll,Jens J. Holst,Bolette Hartmann,Filip K. Knop,Morten Frost,Morten Frost +6 more
TL;DR: Eradication of anaerobic bacteria from healthy adult males had no effect on serum bone turnover markers and neither short nor long-term alterations in serum P1NP, CTX and osteocalcin were observed, and there were no changes in levels of GLP-2, serotonin or sex hormones.
Journal ArticleDOI
Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption
Natasha C. Bergmann,Asger Lund,Sebastian M. Nguyen Heimbürger,Lene Jessen,Mikkel B. Christensen,Tina Vilsbøll,Filip K. Knop +6 more
TL;DR: This investigated the effect of mono- and co-administration of the incretin hormones glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) on bone resorption and formation in overweight/obese men without diabetes.
Journal ArticleDOI
Comment on: Villareal et al. (2009) TCF7L2 Variant rs7903146 Affects the Risk of Type 2 Diabetes by Modulating Incretin Action. Diabetes;59:479–485
TL;DR: It is concluded that the TCF7L2 variant rs7903146 confers reduced incretin effect as a consequence of a reduced insulinotropic effect of the twoincretin hormones, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), although this was actually not tested.